Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26461083 | 0.83 | CYP11B1 (0.32) | CYP11B2CYP11B1PRMT6TDO2 | |
| SCHEMBL30296327 | 0.83 | CYP11B1 (0.32) | CYP11B2CYP11B1PRMT6TDO2 | |
| SCHEMBL31026729 | 0.80 | CYP11B1 (0.46) | CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL26469046 | 0.77 | CYP11B2 (0.43) | CYP11B2CYP11B1TDO2CYP17A1 | |
| SCHEMBL30296491 | 0.77 | CYP11B2 (0.43) | CYP11B2CYP11B1TDO2CYP17A1 | |
| SCHEMBL30296367 | 0.75 | PIK3CA (0.44) | KCNH2 | |
| SCHEMBL30296489 | 0.74 | CYP2A6 (0.50) | CYP11B2CYP11B1 | |
| SCHEMBL30296737 | 0.73 | EPHB4 (0.36) | KCNH2GRIN2BTDO2 | |
| SCHEMBL30296309 | 0.72 | CYP11B2 (0.42) | CYP11B2CYP11B1PRMT5WDR77TLR7 | |
| SCHEMBL30296533 | 0.71 | PIK3CA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | CYP11B2 328/4885CYP11B1 309/4885PRMT5 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.